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ABSTRACT 
Background: Postoperative nausea and vomiting (PONV) are common 
and potentially distressing adverse events (AEs) associated with surgery and 
anesthesia. In patients undergoing laparoscopic cholecystectomy (LC) without 
antiemetic prophylaxis, the incidence of PONV can be as high as 72N. 
Objective: The aim of this study was to investigate the prophylactic anti- 
emetic effects of ondansetron and granisetron in patients undergoing LC when 
these agents are administered before the end of surgery. 
Methods :  Patients classified by the American Society of Anesthesiologist's 
physical status as I or II who were scheduled for elective LC were included 
in this randomized, double-blind, placebo-controlled study. Anesthesia was 
induced with thiopental 5 mg/kg and fentanyl 2 pg/kg, and was maintained 
with isoflurane 1% to 3% in 50% oxygen and 50% nitrous oxide and fentanyl 
as needed. Approximately 20 to 30 minutes before the end of the surgery, the 
patients randomly received either IV ondansetron 100 pg/kg (group O), IV 
granisetron 40 pg/kg (group G), or normal saline (group P). Plasma levels of 
alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were 
determined preoperatively and 24 hours postoperatively. The patients were 
observed for 24 hours for PONV and other possible AEs. Postoperative pain 
intensity was determined using a 10-cm visual analogue scale. Four-point satis- 
faction scores were determined at 24 hours. 
Results: Ninety patients (69 women, 21 men) participated in the study. 
Demographic haracteristics and operative data (duration of surgery and 
anesthesia and amount of intraoperative f ntanyl) were similar in the 3 groups. 
The only AE reported by patients during the 24-hour observation period was 
nonsevere headache. The number of patients experiencing headache was simi- 
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lar in group P, group O, and group G (10 [33%] patients, 6 [20%], and 10 [33%], 
respectively). No significant changes were found in presurgical and postsurgi- 
cal plasma levels of ALT and AST in any group. The mean (SD) satisfaction 
scores in group O and group G (3.0 [0.4] and 3.0 [0.6], respectively) were sig- 
nificantly higher than those in group P (2.5 [0.5]; both, P < 0.01). Immediately 
after surgery (period 0), significantly more patients in the placebo group (21 
[70%]) experienced PONV compared with those in the ondansetron group (9 
[30%]; P< 0.05) and the granisetron group (7 [23%]; P< 0.01). During the 24-hour 
observation period, a significantly greater number of patients in group P (18 
[60%]) required asingle dose of a rescue antiemetic drug compared with those 
in groups O and G (9 [30%] and 6 [20%], respectively; both, P < 0.01). 
Conclusions: Patients administered ondansetron 100 1Jg/kg or granisetron 
40 1Jg/kg 20 to 30 minutes before the end of LC had significantly higher PONV 
control during the 24-hour postoperative observation period than patients 
receiving placebo. However, there were no significant differences between the 
active treatment groups in the incidence of PONV, patient satisfaction, or AEs. 
(Curt TherRes Clin Exp. 2007;68:303-312) Copyright © 2007 Excerpta Medica, Inc. 
Key words: laparoscopic cholecystectomy, postoperative nausea nd vomit- 
ing, ondansetron, granisetron. 
INTRODUCTION 
Postoperative nausea and vomiting (PONV) are common (overall incidence, 
25%-30%) and possibly distressing adverse vents (AEs) related to surgery and 
anesthesia. 1 In patients undergoing laparoscopic holecystectomy (LC) with- 
out antiemetic prophylaxis, the incidence of PONV can be as high as 72%. 2 
When compared with open cholecystectomy, LC has many advantages, uch 
as a smaller scar, shorter hospital stay, and more rapid return to normal daily 
activities. 3 However, the high incidence of PONV in patients not receiving anti- 
emetic prophylaxis decreases the level of postoperative comfort hat might be 
achieved with this minimally invasive surgery and makes antiemetic prophy- 
laxis necessary. 
To control PONV, traditional antiemetic drugs (eg, metoclopramide, dro- 
peridol, and promethazine) have been used successfully. 1,4However, these 
antiemetic drugs are associated with AEs (eg, sedation, dry mouth, and 
extrapyramidal symptoms). 1 The 5-hydroxytryptamine type 3 (5-HT3) receptor 
antagonists have been shown to be effective in the prevention and treatment 
of PONV without significant AEs. 1,2,5 In several studies, 5-7 the selective 5-HT 3 
receptor antagonists ondansetron and granisetron have been found to reduce 
the prevalence of PONV when administered prophylactically. 
For PONV prophylaxis, both ondansetron and granisetron have been recom- 
mended to be administered atthe start of anesthesia. 1,8However, other studies 
have found that antiemetic prophylaxis with these drugs was more efficient 
when they were administered atthe end of surgery. 9,1° 
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The aim of the present study was to investigate the antiemetic prophylactic 
effect of ondansetron and granisetron administered before the end of surgery 
to patients undergoing elective LC. 
PATIENTS AND METHODS 
The study was approved by the Faculty Ethics Committee of the Firat University 
School of Medicine, Elazig, Turkey. All patients provided written informed con- 
sent before participating in the study. 
Consecutive adult patients of both sexes classified as American Society 
of Anesthesiologists physical status I or II u who were scheduled for elective 
LC were enrolled in this randomized, double-blind, placebo-controlled study. 
Patients with a history of PONV and/or motion sickness; patients who were 
pregnant, lactating, or menstruating; those with clinically notable gastrointes- 
tinal, cardiovascular, neurologic, renal, hepatic, or endocrinologic disease (eg, 
obesity, diabetes mellitus); and those who were receiving drugs with known 
antiemetic effects were excluded from the study. All patients were visited by a 
study investigator the day before surgery and were informed about the objec- 
tive of the study and the use of a patient-controlled analgesia (PCA) pump. 
Patients were randomized to receive ondansetron (group O), granisetron (group 
G), or placebo (group P). The investigator collecting the data and the patients 
were blinded to randomization. All study drugs (ondansetron 1001Jg/kg, granisetron 
401Jg/kg, and normal saline) were diluted by a nurse anesthetist toa fixed volume 
of 100 mL and marked with a coded label to ensure the double-blind nature of 
the study. 
Patients were premedicated with IM midazolam 0.05 mg/kg 30 minutes 
before the induction of anesthesia. In the operating room, standard parameters 
(eg, electrocardiography, eart rate, noninvasive arterial blood pressure, tem- 
perature, pulse oximetry, and end-tidal carbon dioxide [CO2] ) were monitored. 
Normal saline (0.9%) was administered intravenously during surgery in all 
groups. Anesthesia was induced with thiopental 5 mg/kg and fentanyl 2 1Jg/kg. 
Vecuronium 0.2 mg/kg was administered to facilitate ndotracheal intubation. 
After tracheal intubation, anesthesia was maintained with isoflurane 1% to 3% 
in a combination of 50% oxygen and 50% nitrous oxide. Supplements of IV fen- 
tanyl 11Jg/kg and IV vecuronium 2 mg were administered as needed. Ventilation 
was controlled mechanically and was adjusted to maintain the end-tidal CO 2 
concentration at 30 to 40 mm Hg. After tracheal intubation, a nasogastric tube 
was inserted to remove gastric contents and air. All patients received a second- 
generation cephalosporin after tracheal intubation. 
Approximately 20 to 30 minutes before the end of surgery, the patients 
received IV ondansetron 100 1Jg/kg, * granisetron 40 1Jg/kg,t or placebo (normal 
saline) over 10 minutes. At the end of surgery, the nasogastric tube was 
*Trademark: Zofer ® (Adeka, Samsun, Turkey). 
tTrademark: Kytril ® (Roche, Istanbul, Turkey). 
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removed and the anesthet ic  drugs were stopped.  Patients received neostig- 
mine 0.03 mg/kg and atropine 0.01 mg/kg to reverse residual neuromuscu lar  
blockade. All pat ients received fentanyl for postoperat ive  analgesia via the 
IV PCA pump after a 25-pg loading dose before t racheal  extubat ion.  The 
PCA pump was programmed to del iver a 0.2-pg/kg bolus of fentanyl with 
a 15-minute lockout interval. Venous blood samples were drawn preopera-  
t ively and 24 hours  postoperat ive ly  to determine plasma levels of alanine 
aminotransferase  (ALT) and aspartate  aminotransferase (AST). 
All pat ients were observed  in the recovery  room during the first post- 
operat ive hour  and then in the ward by the same invest igator (A.Y.) who 
was bl inded to the t reatment  groups. The invest igator determined nausea- 
vomit ing scores  (0 = no nausea, 1 = nausea, 2 = retching and/or  1 vomitus,  
3 = >1 vomitus) by direct  quest ioning of the pat ients at the following post- 
operat ive times: 0 (when the patient first responded to a simple verbal order) 
and 1, 2, 4, 8, 12, and 24 hours.  Patients with a PONV score of _>2 received 
metoc lopramide 10 mg IV as a rescue antiemetic.  The invest igator also 
assessed postoperat ive  pain intensity using a 10-cm visual analogue scale 
(VAS) (0 = no pain to 10 = the worst  pain). At 24 hours,  the invest igator 
recorded rescue ant iemet ic  drug use, complete or incomplete response,  
total fentanyl consumpt ion,  and degree of sat isfact ion (1 = very  unsatisf ied, 
2 = unsatisf ied, 3 = satisfied, 4 = very  satisf ied). Complete response was 
def ined as no PONV and/or  no need for the rescue ant iemetic  drug. 
Statistical Analysis 
Statistical analyses were performed using analysis of variance with the 
Tukey honest ly significant difference correction, Student test, Mann-Whitney 
U test, independent-sample t test, and Z 2 test, where appropriate. All values 
were expressed as mean (SD), number (%), or median (range). P < 0.05 was 
considered significant. All the analyses were performed using the Statistical 
Package for Social Sciences version 12.0 (SPSS Inc., Chicago, Illinois). 
RESULTS 
Ninety patients (69 women, 21 men) were included in the study. There were 
30 patients in each group, and all of the patients completed the study. There 
were no significant differences between the 3 groups in regard to demographic 
characteristics, mean duration of surgery, mean duration of anesthesia, or 
intraoperative total fentanyl consumption (Table I). 
The only AE reported by patients during the 24-hour observation period was 
nonsevere headache. The number of patients experiencing headache was simi- 
lar in group P, group O, and group G (10 [33%], 6 [20%], and 10 [33%] patients, 
respectively). 
All patients had postoperat ive pain scores ranging from 0 to 5 on the VAS. 
No differences were found in mean pain scores or postoperat ive total mean 
fentanyl consumption among the 3 groups (Table II). 
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Table I. Baseline demographic characteristics and operative data in adult patients 
undergoing laparoscopic cholecystectomy (N = 90).* Data are mean (SD) 
unless otherwise noted. 
Ondansetron Group Granisetron Group Placebo Group 
Variable (n = 30) (n = 30) (n = 30) 
Age, y 39.1 (4.8) 41.6 (8.3) 40.6 (9.9) 
Weight, kg 74.9 (10.0) 71.9 (8.8) 73.6 (13.0) 
Height, cm 166.1 (7.1) 164.9 (7.1) 163.5 (8.1) 
Sex, no. (%) 
Female 24 (80) 22 (73) 23 (77) 
Male 6 (20) 8 (27) 7 (23) 
Duration of surgery, min 76.3 (18.6) 79.0 (19.1) 71.8 (23.5) 
Duration of anesthesia, min 89.5 (19.7) 92.1 (19.8) 85.5 (32.3) 
Intraoperative fentanyl, IJg 145.5 (48.7) 156.5 (32.4) 154.1 (46.5) 
*No significant between-group differences were found. 
Table II. Postoperative data and plasma levels of alanine aminotransferase (ALT) 
and aspartate aminotransferase (AST) in adult patients undergoing laparo- 
scopic cholecystectomy (N = 90). 
Ondansetron Group Granisetron Group Placebo Group 
Variable (n = 30) (n = 30) (n = 30) 
Fentanyl, 
mean (SD), pg 107.5 (22.8) 118.5 (22.9) 113.3 (29.5) 
Rescue antiemetic, 
no. (%) 9 (30)* 6 (20)* 18 (60) 
Complete  response ,  
no. (%) 21 (70)t 23 (77)t 9 (30) 
Satisfaction score,* 
median (range) 3.0 (2-4)* 3.0 (2-4)* 2.5 (2-3) 
Headache, no. (%) 6 (20) 10 (33) 10 (33) 
Preoperative, 
mean (SD), IU/L 
AST 20.9 (10.0) 23.3 (11.6) 25.5 (14.3) 
ALT 24.2 (10.0) 30.3 (21.3) 27.3 (15.6) 
Postoperative, 
mean (SD), IU/L 
AST 38.1 (22.6) 29.1 (14.4) 35.7 (8.7) 
ALT 40.5 (20.8) 35.4 (18.9) 40.8 (11.9) 
*P < 0.01 versus placebo. 
tp < 0.001 versus placebo. 
*Scale: 1 = very unsatisfied; 2 = unsatisfied; 3 = satisfied; 4 = very satisfied. 
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Between-group differences in both preoperative and postoperative 
plasma levels of ALT and AST were not statistically significant. The mean 
(SD) satisfaction scores in group O and group G (3.0 [0.4] and 3.0 [0.6], 
respectively) were significantly higher than in group P (2.5 [0.5]; both, P < 
0.01). In the first 24 hours after surgery, the number of patients with com- 
plete response in groups O and G was significantly higher (21 [70%] and 23 
[77%], respectively) compared with that of placebo (9 [30%]; both, P < 0.001) 
(Table II). 
Immediately after surgery (period 0), significantly more patients in the 
P group (21 [70%]) had PONV compared with the O group (9 [30%]; P< 0.05) 
and the G group (7 [23%]; P < 0.01). During the first hour after surgery, sig- 
nificantly more patients in group P (21 [70%]) had PONV than in groups O 
and G (2 [7%] and 6 [20%]; both, P < 0.001) (Table III). In group P, 7 patients 
displayed only nausea 4 hours postoperatively and 6 patients displayed only 
nausea at 8 hours. No patient in group P experienced postoperative vomit- 
ing after 1 hour. No patient in group O or group G experienced PONV after 
1 hour. Persistent vomiting was not observed in any group. 
During the 24-hour observation period, a significantly higher number of 
patients in group P (18 [60%]) required a single dose of a rescue antiemetic 
drug compared with groups O and G (9 [30%] and 6 [20%]; both, P < 0.01) 
(Table II). 
The prevalence and severity of PONV, the number of patients requiring 
a dose of rescue antiemetic drug, and the number of patients who had a 
complete response were similar between the ondansetron and granisetron 
groups. 
Table III. The incidence and severity of postoperat ive nausea and vomit ing  in adult  
patients undergo ing  laparoscopic cholecystectomy (N -- 90). 
Ondansetron Group Granisetron Group Placebo Group 
(n = 30) (n = 30) (n = 30) 
Posto pe rative S co re,* S co re,* S co re,* 
Hour No. (%) mean (SD) No. (%) mean (SD) No. (%) mean (SD) 
0 9 (30) 0.6 (0.9)t 7 (23) 0.4 (0.8)* 21 (70) 1.2 (0.8) 
1 2 (7) 0.1 (0.4)§ 6 (20) 0.3 (0.6)§ 21 (70) 1.3 (0.9) 
2 0 O§ 0 O§ 10 (33) 0.3 (0.4) 
4 0 0* 0 0* 7 (23) 0.2 (0.4) 
8 0 O* 0 O* 6 (20) 0.2 (0.4) 
12 0 0 0 0 0 0 
24 0 0 0 0 0 0 
*Scale: 0 = no nausea; 1 = nausea; 2 = retching and/or 1 vomitus; 3 = >1 vomitus. 
tp < 0.05 versus placebo. 
*P < 0.01 versus placebo. 
§P < 0.001 versus placebo. 
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DISCUSSION 
PONY are observed with all types of surgery and in all patient populations 
when prophylactic antiemetic drugs are not used. 1The prevalence of PONV 
in patients undergoing LC without antiemetic prophylaxis ranges from 43% to 
72%. 2,12 In many studies, the prevalence of PONV has been found to decrease 
significantly with antiemetic prophylaxis. 2,6,7 Traditional antiemetic drugs (eg, 
droperidol and metoclopramide) may be associated with AEs (eg, sedation, dry 
mouth, and extrapyramidal symptoms). The 5-HT 3 receptor antagonists are not 
associated with such AEs, and they have more effective antiemetic activity. 1,2,5 
Therefore, 5-HT 3 receptor antagonists are used to prevent and treat PONV 
after a variety of surgical procedures. 1,5,70ndansetron, thefirst selective 5-HT 3 
receptor antagonist used for the prevention of PONV, and granisetron, another 
selective 5-HT 3 receptor antagonist, have been found to be well tolerated and 
highly effective in preventing and treating PONY. 5-7,12 
The timing of prophylactic antiemetic management might be important. In 
some studies, ondansetron and granisetron were administered at the start of 
anesthesia for PONV prophylaxis. 1,6,8,12 However, 1 study found it was more 
effective to administer ondansetron 4 mg IV at the end of surgery than at the 
start of anesthesia (complete responses, 74% and 71%, respectively; P < 0.05). 9 
Administering these antiemetic drugs at the end of surgery had additional 
benefits, including increased effectiveness of lower doses and greater patient 
satisfaction.9,13 
Ondansetron reaches peak plasma concentration i  20 to 30 minutes after 
intravenous administration. 8 In healthy volunteers, granisetron has also been 
shown to reach peak plasma concentrations 30 minutes after intravenous 
administration. 8 Therefore, intravenous administration of either drug 20 to 
30 minutes before extubation may provide sufficient postoperative antiemetic 
effect. However, ondansetron and granisetron may not be sufficiently effective 
when administered at the end of surgery or just before extubation. So et a114 
found that patients administered a single 4-mg dose of IV ondansetron at the 
end of LC (just before tracheal extubation) had similar PONV scores to the pla- 
cebo group at the end of the study. The authors concluded that ondansetron 
4 mg after LC did not reduce the prevalence of nausea nd vomiting. Quaynor 
and Raeder 4administered patients IV metoclopramide 20mg or ondansetron 
8 mg after surgery. Despite the high doses, the overall prevalence of PONV was 
high (47% with metoclopramide and 43% with ondansetron). In both studies, 
the high rate of PONV might be attributed to the delay in the administration 
of antiemetic drugs. Because the mean (SD) plasma elimination tl/2 of both 
ondansetron and granisetron are relatively short (-2.8 [0.6] and -3.1 [1.2] hours, 
respectively), 1516 patients may need to receive a repeat dose. However, for 
short surgical procedures, these drugs may be administered during anesthesia 
induction. 
In the present study, 70% of patients in the placebo group experienced PONV 
during the 24-hour postsurgical observation period, while PONV was 30% with 
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ondansetron 100 pg/kg and 23% with granisetron 40 pg/kg administered before 
the end of LC. No significant differences were found between the groups in the risk 
factors for PONV (eg, patient demographic characteristics, operative procedure, 
anesthesia dministration procedure, anesthetics used, and intraoperative and 
postoperative analgesic onsumption). Therefore, we believe that the differences 
in PONV control observed were associated with the antiemetic drugs used. 
The adult dose of ondansetron recommended to prevent PONV is 4 mg. 8 
However, in a randomized, double-blind, placebo-controlled study of 2119 pa- 
tients (aged >12 years), Kovac et a117 found that the 4-mg dose of ondansetron 
was not effective. In a meta-analysis of 53 trials with 7177 patients receiving 
24 different ondansetron formulations, Tramer et a118 recommended IV ondanse- 
tron 8 mg for PONV prophylaxis. In a randomized, double-blind comparison 
study by Zarate et al, 13 outpatients undergoing otolaryngologic procedures 
received IV ondansetron 4 or 8 mg <30 minutes before the end of surgery. 
The 8-mg dose was not found to be significantly more effective than ondanse- 
tron 4 mg. The ondansetron dose used in the present study was within the 
recommended range (4-8 mg) for PONV prevention. 
To prevent PONV after various surgical procedures, the optimal dose of 
granisetron was found to be 40 lJg/kgl9,2°; higher doses have not been found 
to be more effective. 19,21 Similarly, granisetron 40 pg/kg was found to be the 
minimum effective dose for preventing PONV in patients undergoing LC. 12 
Therefore, granisetron 40 pg/kg was used in this study. 
A randomized, double-blind, placebo-controlled study 2comparing the anti- 
emetic effects of ondansetron and granisetron i  PONV found no difference in 
effectiveness between the 2 drugs. A dose of IV granisetron 3 mg was found 
to provide no more effective antiemetic prophylaxis than ondansetron 4 mg 
in patients undergoing LC. A 2003 study 22 found granisetron to be superior to 
ondansetron i the prevention of PONV after outpatient gynecologic laparo- 
scopic surgery (administered 2 minutes before induction of general anesthe- 
sia); granisetron 2 mg IV was found to be more effective than ondansetron 4 mg 
IV (emetic episodes were observed in 7% of patients who had received intrave- 
nous granisetron and 20% in those who had received ondansetron). In the study 
by Naguib et al, 2 a dose of IV granisetron 3 mg was comparable to ondansetron 
4 mg with regard to effective antiemetic prophylaxis in patients undergoing LC. 
The most frequently reported AEs of 5-HT 3 receptor antagonists are head- 
ache (<2%) and dizziness (12%). 4,5,8 Transient elevated plasma levels of AST and 
ALT without clinically significant hepatic changes have also been reported. 8 
In 1 study, 15-HT 3 receptor antagonists were not found to affect liver function 
tests. Another study 1° found preoperative and postoperative plasma amino- 
transferase activities to be similar and also found no difference compared 
with placebo. In the present study, no significant differences were found in 
preoperative and postoperative plasma aminotransferase levels. The only 
patient-reported AE was nonsevere headache; the prevalence of headache was 
similar in the 3 groups. 
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Limitations 
This study included a relatively small sample size to identify differences in 
the prevalence of PONV. However, when the previous studies are taken into 
account, we believe that the sample size we used was sufficient. Another limi- 
tation was the lack of medication groups at the start of anesthesia to use for 
comparisons. Comparisons were based on the placebo group and the previous 
studies. 
CONCLUSIONS 
Patients administered ondansetron 100 pg/kg or granisetron 40 pg/kg 20 to 
30 minutes before the end of LC had significantly higher PONV control during the 
24-hour postoperative observation period than patients administered placebo. 
However, there were no significant differences between the active treatment 
groups in the prevalence of PONV, patient satisfaction, or AEs. No serious AEs 
were observed with either drug. 
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